High PTGS2 expression in post-neoadjuvant chemotherapy-treated oesophageal adenocarcinoma is associated with improved survival: a population-based cohort study Aims: High prostaglandin endoperoxide synthase-2 (PTGS2) enzyme expression in oesophageal adenocarcinoma has been shown to independently predict poor prognosis; however, the evidence is inconsistent. The aim of this study was to investigated the association between PTGS2 expression and prognosis in patients with oesophageal adenocarcinoma. Methods and results: A cohort of 135 patients with oesophageal adenocarcinoma who received neoadjuvant chemotherapy and surgery from 2004 to 2012 was identified in the Northern Ireland Cancer Centre. Tissue microarrays were created in the Northern Ireland Biobank, with triplicate cores being sampled from each tumour. Immunohistochemical PTGS2 expression was scored by two independent assessors, with intensity and proportion of tumour staining being used to calculate H-scores for each patient. Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for overall and cancer-specific survival, and recurrencefree survival by PTGS2 expression, with adjustment for potential confounders. Patients were followed up for a mean of 3.0 years (standard deviation 1.8 years). The PTGS2 expression cut-off value was determined from the median H-score of the cohort (270/300). High (n = 79), as compared with low (n = 56), PTGS2 expression was associated with improved cancer-specific survival (adjusted HR 0.56, 95% CI 0.33-0.94; P = 0.03). PTGS2 expression was not significantly associated with recurrence-free survival (adjusted HR 0.85, 95% CI 0.52-1.38; P = 0.51). Conclusions: High PTGS2 expression in oesophageal adenocarcinoma tissue was associated with improved overall and cancer-specific survival, in contrast to previous evidence. As this is the first study of its kind to include patients who had undergone neoadjuvant chemotherapy, further studies are needed to clarify these associations.
Introduction
Oesophageal cancer is the eighth most common cancer worldwide, 1 with a poor prognosis (a 5-year survival rate of 15% in the UK 2 ). As survival of patients with this cancer remains poor, new treatments to supplement chemotherapy, radiotherapy and surgery are being investigated, including the use of commonly prescribed medications, such as aspirin. 3 There is also increasing interest in the development of prognostic biomarkers, which could facilitate these treatment decisions.
Preclinical research has shown that prostaglandin endoperoxide synthase-2 (PTGS2) (also known as cyclooxygenase) enzyme activity is associated with inflammation and tumour growth, and is a potential prognostic biomarker. 4 PTGS2 converts arachidonic acid to prostaglandins and other eicosanoids, which can induce carcinogenesis through enhanced inflammatory changes and cellular proliferation. 5 High PTGS2 expression is associated with additional carcinogenic processes, including increased intratumoral microvessel density and reduced apoptosis. 6, 7 Specifically, oesophageal cancer cells are known to have greater expression of PTGS2 than normal tissue. [8] [9] [10] Although the association between PTGS2 expression in oesophageal squamous cell carcinoma tissue and survival has been extensively studied, 11 few studies have investigated the adenocarcinoma subtype. Moreover, results are inconsistent, with four [12] [13] [14] [15] of the seven studies finding that PTGS2 expression was not associated with survival, and the remaining three [16] [17] [18] studies finding that survival was worse with high PTGS2 expression. Furthermore, only two studies have investigated cancer-specific survival outcomes; one found that high PTGS2 expression was associated with decreased overall survival but not decreased cancer-specific survival, 14 and the other showing no association for either outcome. 12 Also, all previous studies of oesophageal adenocarcinoma excluded patients who had undergone chemotherapy, which is now a standard component of management. Further studies are needed to help clarify the association between PTGS2 expression and survival in patients with oesophageal adenocarcinoma.
The aim of this study was to investigate the association between PTGS2 expression and survival outcomes in a cohort of patients diagnosed with oesophageal adenocarcinoma who underwent neoadjuvant chemotherapy.
Materials and methods

D A T A S O U R C E S
Clinical data for this study were obtained from the Northern Ireland Cancer Centre electronic Clinical Oncology Information System (COIS). Tissue specimens were obtained from the Northern Ireland Biobank. This biobank contains tissue samples obtained from regional Health Trust pathology departments for use in research. 19 It has ethical approval from the Office for Research Ethics Committees Northern Ireland (ORECNI; reference 16/ NI/0030) to obtain, store and distribute samples for research purposes. The Northern Ireland Biobank granted approval for this study (study number NIB15-0176).
S T U D Y D E S I G N A N D C O H O R T
Individuals with newly diagnosed oesophageal cancer between 2004 and 2012 were identified in the Northern Ireland Cancer Centre database. The cohort was restricted to all patients with nonmetastatic oesophageal adenocarcinoma who underwent surgical resection following neoadjuvant chemotherapy. The Northern Ireland Biobank retrieved oesophageal adenocarcinoma resection specimens for these patients from the archives, creating a population-representative cohort. Patients were excluded from the analysis if there were no tumour cells present in their tissue samples or if clinicopathological data were insufficient. Oesophageal all-cause and cancer-specific deaths (primary cause of death recorded as oesophageal or gastric cancer) were identified from the vital statistics in the COIS, and follow-up began from the date of oesophageal adenocarcinoma diagnosis. Patients were followed up until their last review appointment, date of recurrence, date of death, or end of study follow-up (31 December 2014). Overall survival was defined as survival until death from any cause, and cancer-specific survival was defined as survival time until death for which the primary cause was oesophageal adenocarcinoma. Tumour recurrence was defined as the development of local or distant cancer during follow-up. Recurrence-free survival was defined as the time from the start of follow-up until diagnosis with a recurrence or death from any cause. The study has been reported in accordance with the REMARK recommendations (Table S1 ). 20 
T I S S U E M I C R O A R R A Y ( T M A ) C O N S T R U C T I O N
A TMA was created in the Northern Ireland Biobank, including three tumour cores from each patient's surgical resection specimen. A detailed description of TMA construction methods within the Northern Ireland Biobank is given elsewhere. 21, 22 
Immunohistochemistry (IHC) was performed on TMA sections in the Northern Ireland Molecular Pathology Laboratory by use of an in-house-optimised protocol for PTGS2 (rabbit monoclonal antibody; Ventana Medical Systems, Tuscon, AZ, USA; catalogue number 760-4254). Sections were cut at 4 lm on a rotary microtome, dried at 37°C overnight, and then used for IHC, which was performed with an automated immunostainer (PTGS2; Cell Conditioning solution 1 for 32 min and primary antibody for 16 min on a Ventana BenchMark; Ventana Medical Systems). Antigen-binding sites were detected with the Optiview detection kit (Ventana Medical Systems, Tuscon, AZ, USA). All sections were visualised with diaminobenzidine, counterstained with haematoxylin, and mounted in DPX. Test tissue with no primary antibody was used as a negative control. Sections were scanned with an Aperio AT2 scanner (Ventana Medical Systems, Tuscon, AZ, USA) to be viewed electronically.
S C O R I N G M E T H O D S
Tissue microarray specimens were reviewed and scored with PathXL electronic image viewer. PTGS2 expression was assessed by two independent observers (A.D.S. and J.T.) who were blinded to clinical data. Any discordant results were clarified by discussion between A.D.S., J.T., and D.T.M. Scoring was achieved by determination of the proportion of tumour cells staining positive, calculated as a percentage, and the intensity of cytoplasmic staining (0 = no staining, 1 = weak intensity, 2 = moderate intensity, and 3 = strong intensity) ( Figure 1 ). These two values were multiplied to produce an H-score for each core sample, 23 with minimum and maximum possible scores of 0 and 300, respectively.
C L I N I C A L V A R I A B L E S
Demographic and clinical information included age at diagnosis, sex, date of diagnosis, smoking, and history of alcohol use. The primary tumour location was categorised into the lower third of the oesophagus and the gastro-oesophageal junction. The Siewert classification 24 was used to categorise junctional tumours (1, adenocarcinoma of the distal oesophagus; 2, true carcinoma of the cardia arising at the gastro-oesophageal junction; and 3, subcardial gastric cancer infiltrating the distal oesophagus). Response to chemotherapy on positron emission tomography (PET) scan (PET responder), circumferential resection margin (CRM) status, tumour grade and lymphatic vascular invasion data were also retrieved. Pathological staging was defined according to the International Union Against Cancer TNM system, 7th Edition. 25 A Mandard score of ≤2 indicated a pathological response in the resection specimens. Missing categories were formed when there was an absence of data (smoking and PET responder).
S T A T I S T I C A L A N A L Y S I S
Maximum H-scores from triplicate cores for each patient were used to classify patients according to PTGS2 expression. The maximum H-score of each patient's three cores was selected as the overall Hscore for that patient. The median value of the cohort's overall H-scores was 270, which was selected as a cut-off value to define low/high PTGS2 expression.
Differences between clinical and pathological characteristics by PTGS2 expression were calculated with chi-squared tests. Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for overall and cancer-specific survival according to tumour tissue PTGS2 expression (high versus low). Univariable analysis was first conducted, followed by multivariable analysis, which included adjustment for age, smoking history, sex, surgical nodal stage, tumour location, PET responder status, CRM, tumour grade, and vascular lymphatic invasion. Adjustment for alcohol consumption and tumour 'T' stage was tested but omitted in backwards selection from the final multivariate model, owing to it having a limited impact on the results. A positive PET response was defined as a ≥35% reduction in the maximum standardised uptake value of the primary tumour between pre-chemotherapy and post-chemotherapy scans. Associations between tumour PTGS2 expression and recurrence-free survival were also investigated. Additionally, outcomes were investigated in sensitivity analyses restricting the cohort to patients diagnosed with gastro-oesophageal junctional tumours. Events are defined as death from any cause for overall survival, death from oesophageal adenocarcinoma for cancer-specific survival, and recurrence or death from any cause in analysis of recurrence-free survival. Analysis was performed with STATA version 14 (StataCorp LP, College Station, TX, USA).
Results
P A T I E N T C O H O R T
A total of 158 patients with oesophageal adenocarcinoma underwent neoadjuvant chemotherapy followed by surgery between 2004 and 2012 in Northern Ireland. Fifteen patients were excluded because of absence of tumour in all three core samples, and four patients were excluded because of lack of clinical and/or pathological data. A further three were excluded because of complete response following neoadjuvant chemotherapy, and one patient was excluded because there were metastases present at the time of surgery, leaving 135 for the main analysis ( Figure 2 ). The mean follow-up time was 3.0 years (minimum 5 months; maximum 9 years), during which there were 80 deaths, 75 of which were due to oesophageal adenocarcinoma, and 78 recurrences. Table 1 shows patient characteristics by PTGS2 expression. The majority of the cohort were male (77%), and the mean age at diagnosis was 62 years. The most common tumour site was the gastro-oesophageal junction (85%), and 43% of patients were PET responders. Five patients had a pathological response (Mandard score of ≤2), whereas 130 had a Mandard score of >2.
P A T I E N T C H A R A C T E R I S T I C S
A S S O C I A T I O N O F P T G S 2 W I T H C L I N I C O P A T H O L O G I C A L V A R I A B L E S
High PTGS2 expression was more frequently observed in patients responding to chemotherapy on PET scan. There were no differences between low/high PTGS2 expression and the other clinicopathological variables investigated (Table 1) . After Bonferroni corrections for multiple comparisons, the difference between the two groups was no longer apparent. 
A S S O C I A T I O N B E T W E E N P T G S 2 E X P R E S S I O N
S E N S I T I V I T Y A N A L Y S E S
When the cohort was restricted to only those patients with tumours located in the gastro-oesophageal junction, high PTGS2 expression was associated with 48% improved overall survival and 50% improved cancer-specific survival (respectively: adjusted HR 0.52, 95% CI 0.30-0.90; and adjusted HR 0.50, 95% CI 0.28-0.88). As in the main analysis, there was no significant association between high/low PTGS2 expression and recurrence-free survival (adjusted HR 0.71, 95% CI 0.42-1.21) ( Table 3 ). As only 15% of the tumours were situated in the distal oesophagus, this sensitivity analysis was conducted only on junctional cancers.
Discussion
In this population-based cohort of patients with oesophageal adenocarcinoma, we found that PTGS2 expression was associated with improved overall and cancer-specific survival. Although HRs were reduced in the analysis of PTGS2 expression and recurrencefree survival, the results were not statistically significant. Similar associations to those in the main analysis were observed when the analysis was restricted to tumours located at the gastro-oesophageal junction. There have been seven previous survival studies of patients with oesophageal adenocarcinoma and PTGS2 expression [12] [13] [14] [16] [17] [18] 26 ; however, one combined its analysis with oesophageal squamous cell carcinoma cases. 26 Three of these studies found that high PTGS2 expression was associated with poorer overall survival, [16] [17] [18] consistent with a 2017 metaanalysis by Hu et al. (pooled HR 2.13, 95% CI 1.62-2.79). 11 Of the two previous studies investigating cancer-specific survival, Prins et al. found that, although PTGS2 expression was an independent predictor of poor overall survival, associations were nonsignificant in an analysis of cancer-specific survival after adjustment for confounders (HR 1.55, 95% CI 
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0.95-2.53).
14 Similarly, in a study of 66 patients, Lagorce et al. showed that PTGS2 expression was not associated with cancer-specific survival. 12 The differences in improved survival for patients with high PTGS2 expression tumours observed in this study contrast with previous evidence. This may be because all patients in our cohort underwent neoadjuvant chemotherapy, whereas previous studies all excluded patients who received any chemotherapy (Table 4) . PTGS2 is up-regulated during inflammation and immune response activation, 27 and, as chemotherapeutic agents can stimulate this local immune response 28 and are known to increase survival, 29 it is possible PTGS2 expression is increased in patients in whom neoadjuvant chemotherapy has been most effective.
Comparison with previous studies is limited, however, owing to the variety of techniques used to score the staining in tumour specimens. There was substantial variation in low/high cohort proportions across studies (high expression proportion range of 26.5-79.3%), influenced by the use of different methods to calculate low/high expression cut-off values (Table 4) . Also, although each of the former studies used staining intensity to score the tissue specimens, only three also took into account the proportion of cells staining positive to calculate an overall staining score. Furthermore, there was only one previous study which used the same H-score design and median score method to determine a cut-off value for low/high PTGS2 expression as in our study. 18 When recurrence-free survival was investigated, there was suggestion of a protective effect (HR 0.85); however, it was not statistically significant. The cause for the lack of a significant association being observed is unclear. A potential explanation may be that, despite the large number of recurrences in the group with high PTGS2 expression, these may be local relapses that could be treated with radiotherapy, which would have much less of an impact on overall survival than in those developing metastatic disease. Although some research has shown that high PTGS2 expression is associated with an increased risk of recurrence in patients with oesophageal adenocarcinoma, 13, 16, 18 this was not observed in all studies.
14 Moreover, only one of these studies investigated recurrence-free survival in patients with oesophageal adenocarcinoma, finding that high PTGS2 expression was significantly associated with poor survival after 3 years of follow-up. 13 Owing to the paucity of evidence, further cohort studies investigating recurrence-free survival are required.
Restricting the analysis to junctional tumours had little effect on the estimates observed for the total cohort, in which high PTGS2 expression was associated with improved overall and cancer-specific survival. It has been suggested that cancer at the gastro-oesophageal junction is an independent disease from distal oesophageal and gastric cancer, in terms of epidemiology, risk factors, and pathophysiology. 30 Furthermore, the approach to surgical resection is different for junctional tumours and distal adenocarcinomas, whereby cancers at the gastro-oesophageal junction often undergo partial or total gastrectomy in CI, Confidence interval; CSS, Cancer-specific survival; HR, Hazard ratio; NR, Not reported; OS, Overall survival. *0 = no staining; 1 = weak intensity; 2 = moderate-strong intensity in 10-90% of cells; 3 = strong intensity in >90% of cells. †0 = no staining; 1 = weak intensity; 2 = medium intensity; 3 = strong intensity; multiplied by score for percentage of cells stained (0 = 0-4%; 1 = 5-29%; 2 = 30-59%; 3 = 60-100%). ‡0 = no staining; 1 = light/moderate intensity or <50% of cells stained; 2 = strong intensity and 100% of cells stained. §Significant for poor survival. ¶0 = no staining; 1 = weak intensity; 2 = medium intensity; 3 = strong intensity; multiplied by score for percentage of cells stained (0 = 0-4%; 1 = 5-29%; 2 = 30-59%; 3 = 60-100%). **0 = no staining; 1 = weak intensity; 2 = moderate intensity; 3 = strong intensity; multiplied by score for percentage of cells stained. The median value was used for the cut-off. † †0 = no staining; 1 = weak intensity; 2 = moderate intensity; 3 = strong intensity.
addition to oesophagectomy. [31] [32] [33] Thus, subgroup analysis restricted to only gastro-oesophageal junction-situated tumours created a more homogeneous group, showing that these patients have similar associations between PTGS2 expression and prognosis as the whole study cohort.
A particular strength of our study is the population-based design, as the study captured all oesophageal adenocarcinoma patients who underwent neoadjuvant chemotherapy followed by surgical resection, for curative intent, in Northern Ireland over the study time period. This is the first study to use a cohort of patients who had undergone neoadjuvant chemotherapy, which is now standard for oesophageal adenocarcinoma management. 31 Therefore, our cohort more accurately reflects current practice than all previous studies. Although tumour heterogeneity is a recognised phenomenon that can affect molecular studies, we reduced its impact by using triplicate cores for each patient.
A limitation of this study is potential bias from confounding by unmeasured factors in the tumour microenvironment, which include endogenous hormone activity, genomic variation, and environmental exposures. 34 Ideally, we would also have investigated PTGS2 expression in the diagnostic oesophageal cancer biopsies pre-chemotherapy; however, sufficient biopsy tissue was not available. Finally, our study is limited by a lack of data on the use of inhibitors of the PTGS2 enzyme pathway, such as non-steroidal anti-inflammatory drug medication.
In conclusion, high PTGS2 expression in oesophageal adenocarcinoma tissue was associated with improved survival, in contrast to previous evidence. There was no evidence of an association between PTGS2 expression and recurrence-free survival. The associations observed may be due to the influence of neoadjuvant chemotherapy. Further studies, with additional investigation of interactions between medication use, PTGS2 expression, and prognosis in patients diagnosed with oesophageal adenocarcinoma, would be of value to clarify these associations.
